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Distribution bias analysis of
germline and somatic singlenucleotide variations that impact
protein functional site and
neighboring amino acids
Yang Pan1,*, Cheng Yan1,*, Yu Hu1, Yu Fan1, Qing Pan2, Quan Wan1, John Torcivia-Rodriguez1 &
Raja Mazumder1,3
Single nucleotide variations (SNVs) can result in loss or gain of protein functional sites. We analyzed
the effects of SNVs on enzyme active sites, ligand binding sites, and various types of post translational
modification (PTM) sites. We found that, for most types of protein functional sites, the SNV pattern
differs between germline and somatic mutations as well as between synonymous and non-synonymous
mutations. From a total of 51,138 protein functional site affecting SNVs (pfsSNVs), a pan-cancer
analysis revealed 142 somatic pfsSNVs in five or more cancer types. By leveraging patient information
for somatic pfsSNVs, we identified 17 loss of functional site SNVs and 60 gain of functional site SNVs
which are significantly enriched in patients with specific cancer types. Of the key pfsSNVs identified in
our analysis above, we highlight 132 key pfsSNVs within 17 genes that are found in well-established
cancer associated gene lists. For illustrating how key pfsSNVs can be prioritized further, we provide a
use case where we performed survival analysis showing that a loss of phosphorylation site pfsSNV at
position 105 in MEF2A is significantly associated with decreased pancreatic cancer patient survival rate.
These 132 pfsSNVs can be used in developing genetic testing pipelines.
With the advancement of high-throughput sequencing (HTS) technology, the cost of sequencing the human
genome has dropped significantly1,2. However, while many biologists expected that genome sequencing could
solve human health issues in a short period of time, complex diseases, such as cancer, still remain difficult to
tackle3. In the field of cancer genomics, several international collaborations, such as The Cancer Genome Atlas
(TCGA) (http://cancergenome.nih.gov/), International Cancer Genome Consortium (ICGC)4, have provided
useful HTS based genomics data by sequencing a large number of tumor samples across cancer types5–7. The
availability of large number of samples across different types of cancer enables pan-cancer analysis which explores
via comparative analysis various cancer genomes originating from different tumor types8,9. By investigating the
similarities and differences of cancer genomes and cellular characteristics across cancer types, tumor heterogeneity has been better understood10,11 and a number of cancer associated pathways and genes have been identified7,12–14. Furthermore, such analysis can reveal how mutations affect protein function. Our previous study8
shows the landscape of protein functional site affecting non-synonymous single-nucleotide variations (nsSNVs)
across cancer types. In the current study we extensively investigate the abundance or depletion of SNV (both synonymous and non-synonymous) occurrence in different protein functional site type and the immediate region of
the protein functional site. We also perform a comparative study on the SNV occurrence between germline and
somatic mutations impacting different functional sites. Previous studies show that synonymous mutations are not
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Figure 1. Flowchart of the distribution bias analysis of protein functional site affecting single nucleotide
variations (pfsSNVs).

always silent and they are able to cause changes in protein expression, conformation and function15–19. Therefore,
we also compare the frequencies of synonymous and non-synonymous mutations on protein functional sites.
Since proteins are the foundational and functional blocks of living organisms, how genomic alterations of
protein coding genes affect protein functionality is an important question. While many previous publications
have focused on genes through pan-cancer analysis, our efforts extend the utility of a pan-cancer analysis by
examining the effect of genomic alterations on protein functional sites. To this end, we have retrieved a comprehensive collection of SNVs and protein functional sites, including post-translational modification (PTM),
ligand binding site, and enzyme active site, from a variety of data sources. Somatic mutations were retrieved
from COSMIC20, UniProtKB21, TCGA (http://cancergenome.nih.gov/), and ICGC4. Germline mutations were
retrieved from dbSNP22. All SNVs were unified and mapped to amino acid positions. To facilitate the pan-cancer
analysis, the original annotated cancer types retrieved from source databases were mapped to Disease Ontology
(DO) slim terms23. Protein functional sites were retrieved from UniProKB sequence feature (FT) line21, NCBI
Conserved Domain Database (CDD)24, and dbPTM25. By integrating SNVs and protein functional sites, we can
identify functional site affecting SNVs (pfsSNVs) for downstream analysis.
In this study, we first obtained a global perspective on how germline and somatic mutations are distributed at
the proteome level, especially on various protein functional sites through integrating 3,342,377 SNVs (1,501,666
germline mutations and 1,840,711 somatic mutations) and 268,478 known and curated PTM sites, binding sites
and enzyme active sites. Then we created a framework to facilitate this SNV prioritization process using observed
frequency in patients and cancer type information.

Materials and Methods
SNV dataset.

As the flowchart in Fig. 1 shows, somatic coding mutations were extracted from ICGC (version v0.10a), TCGA (release January 27, 2015), COSMIC (version v73), IntOGen (release 2014.12), and ClinVar
(release 20150205). All somatic mutations were unified and then annotated using ANNOVAR26. Cancer types
were mapped to DO Cancer Slim terms23 for cancer term unification. Frequency of a certain mutation was either
calculated based on patient ID or was directly extracted from the downloaded files. All integrated information
is stored and can be downloaded from the BioMuta database8. SNVs annotated as the same variation but from
different sources/patients were collapsed into a single entry, but all relevant source information was maintained.
Germline coding mutations were collected from dbSNP (build 142) database. Minor Allele Frequency (MAF)
and “Common/Rare SNP” tags were directly extracted from dbSNP. All SNVs were translated and mapped to the
UniProtKB complete human proteome set (downloaded in January 2015) through a pairwise-alignment based
pipeline for unification and downstream protein functional site analysis.

Protein functional site dataset.

Protein post-translational modification (PTM), binding, and enzyme
active site annotation were extracted from three different sources: dbPTM 3.025, UniProtKB/Swiss-Prot feature
(FT) line (January 2015), and CDD features (January 2015). Only experimentally verified data were retrieved
from dbPTM 3.0 and UniProtKB. Duplicates and conflicted accessions were removed. Variants with the same
annotation from different sources were collapsed into a single data point while maintaining source information.
Modification data was extracted using PTMlist, a controlled vocabulary provided by UniProtKB/Swiss-Prot. The
NCBI CDD-based annotation of functional sites was retrieved using BATCH CD-Search against CDART database27. Entries such as domains, repeats, and motifs with longer than five consecutive amino acids were not
considered. Filtered sites were categorized manually into various types of PTM sites, active sites, and binding sites
with original annotations maintained in a separate column. Other PTM records were adopted based on dbPTM
3.0 which collects PTM data from more than 10 different sources25.
All entries were unified based on the UniProtKB complete human proteome set downloaded from UniProtKB
on January 2015, which is identical to the proteome used for SNVs dataset unification.
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Mapping SNVs to protein functional sites and the neighboring positions.

The general process of
mapping SNVs to protein functional sites includes loading the SNV file into matrix of “UniProt accession with
UniProt Position” and match it to the protein functional site matrix. Once the protein accession and position are
matched, additional steps were used to evaluate if this SNV caused a substitution at the functional site or not. If
the SNV is a substitution, we also consider the known amino acid tolerance for corresponding PTM type, if the
substitution replaces the original residue with a residue which cannot be modified as a PTM or function as an
active site. The output file provides a tab-delimited file containing all SNVs and affected protein functional site
information. A SNV ratio based on SNV numbers divided by proteome length was calculated for expected SNV
number as well as the statistical significance using methods described earlier8. The SNV occurrence between
protein functional site and all other amino acid located within +/−20 amino acids was compared and the significance was evaluated through one sample t-test.

SNV-caused gain of protein phosphorylation and glycosylation site prediction. NetNGlyc (v1.0)

and NetPhosK (v1.0) were used to predict SNV-caused gain of protein phosphorylation and N-glycosylation
site28,29. 21 mer and 5 mer were set as the effective segment length of input sequences for phosphorylation and
glycosylation site prediction respectively. For parameters, ESS filter and threshold 0.6 were applied for NetPhosK,
while a score 0.6 is required for NetNGlyc prediction result. Both protein reference sequence and mutated
sequence were used as input to the NetNGyc and NetPhos in order to minimize false positives by subtracting
background predicted sites.

Statistical significance of amino acid based pfsSNV occurrence. To investigate whether the distinct
frequency of SNV on protein functional sites is caused by different amino acid mutation rate, we conducted
amino acid based binomial test on pfsSNV occurrence.
First, for each type of amino acid (denote as A), we first calculate the probability of A to be a F type of protein
functional site, calculated as following:
p A (F ) =

n A (F )
,
LA

(1)

where LA denotes total number of amino acid A on human proteome, nA(F) denotes the total number of positions
for a specific functional site with amino acid A. Thus, amino acid based protein functional site rate pA(F) can be
derived from our protein functional site dataset.
Then, we calculated the expected number of pfsSNVs nA(E) for each type of amino acid:
n A (E ) = N A p A (F ) = N A

n A (F )
,
LA

(2)

where NA is total number of variations with amino acid type A. nA(E) is then used to derive if the given type of
pfsSNV occurrence on the given amino acid type A is enriched or depleted.
Next, after obtaining from our SNV dataset the value of observed pfsSNV nA(O) for a specific A and F, the
binomial test was performed according to Mi et al.30, and the p-value was calculated as the total probabilities
to observe nA the same as or more extreme (larger if nA(O) is larger than expected and smaller otherwise) than
nA(O), which measures the deviance degree between an expected ratio (nA(E)/NA or pA(F)) and an observed ratio
(nA(O)/NA):

( )
( )

 N A
n
N A−n
NA
, if nA (O) > nA (E )
 ∑ n =n A (O) n pA (F ) (1 − pA (F ))
,
p − value = 

n A (O) N
A p (F )n (1 − p (F ))N A − n , if n (O) < n (E )
A
A
 ∑ n =0
A
A
n


(3)

Comparing to our previous study where the same expected SNV rate applying to all protein functional site8,
advantage of this background SNV rate is that this allows each type of protein functional site having different
expected SNV rates given different components of amino acid as their donor site.

Pan-cancer clustering of pfsSNV profiles.

In order to investigate the somatic pfsSNV occurrence pattern in each cancer type, a pan-cancer analysis was performed. The observed and expected somatic mutation
occurrence among each cancer type among different protein functional site type was calculated following same
rule described under ‘Mapping SNVs to protein functional sites and the neighboring positions’. Basically the
observed value is the mutation occurrence on a type of protein functional site while expected value is the average
of neighboring mutation occurrence. And the fold change was used as a metric to perform hierarchical clustering
(HC). The heat map was generated via the R package ggplot version 2.17.031.

pfsSNVs prioritization criteria. Two distinct criteria were used to prioritize pfsSNV: a) pfsSNVs that exist

across 5 or more cancer types, b) pfsSNVs that are enriched in patients with certain cancers. To do this we leveraged TCGA patient counts mapped to our mutation dataset to identify key pfsSNVs. We combined pfsSNVs that
can cause either a loss or gain of functional site. The Binomial test described above (section “Statistical significance of amino acid based pfsSNV occurrence”) was applied to identify pfsSNVs that is significantly associated
with a certain cancer type based on enrichment in patients with that cancer. In this calculation, we calculated the
expected probability of any type of pfsSNV occurring in a patient in a cancer type C:
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Somatic
Mutation

Germline
Mutation

Functional
Site

Somatic
pfsSNV
Mapped

Germline
pfsSNV
Mapped

Total
Mutations
Mapped

Previous Dataset

994,339

710,946

259,216

25,390

13,159

38,549

Current Dataset

1,840,711

1,501,666

268,478

30,848

18,619

49,467

Table 1. Position based* summary of comparison between the previous and current datasets. *Statistics
summarized in Table 1 is amino acid position based where different functional types occupying the amino acid
position are counted as one.

Previous Version of Dataset
Somatic
Mutation

Germline
Mutation

512

351

Ubiquitination

1,214

Phosphorylation
N-linked glycosylation sites

Current Version of Dataset

%Increase

Total

Somatic
Mutation

Germline
Mutation

Total

Increases by

863

691

432

1,123

30.1%

841

2055

1562

1052

2,614

27.2%

5,466

3917

9383

7373

5282

12,655

34.9%

2,375

1,997

4,372

3,217

2,630

5,847

33.7%

O-linked glycosylation

97

108

205

126

115

241

17.6%

Methylation

163

61

224

208

74

282

25.9%

Crotonylation

42

10

52

57

22

79

52.0%

Nitrosylation

32

43

75

51

48

99

32.0%

Active sites

1,574

811

2385

2,084

1,040

3,124

31.0%

Binding sites

12,286

6,395

18,681

16,630

8,444

25,074

34.2%

Total

23,761

14,534

38,295

31,999

19,139

51,138

33.5%

Acetylation

Table 2. pfsSNVs based* summary of the previous and current datasets. *Statistics summarized in Table 2 is
pfsSNVs based where different functional types occupying the amino acid position are counted separately.

pC (M ) =

nC (E )
E (nC (M ))
=
NC
NC

(4)

where NC is the total number of patient in cancer type C, and nC(M) is the number of patient harboring a specific
pfsSNV M in cancer type C. nC(E) is the expected number of patient in cancer type C for a given pfsSNV M for
any functional types. Then the p-value was calculated as the sum of probabilities of observing number of patients
the same as or more extreme (larger if the observed number of patients is larger than expected number, E(nC(M)),
and lower if the observed number is smaller than E(nC(M))) than the observed number of patients nC(O) in the
sample with the same cancer, NC.

( )
( )

 N C
 ∑ n =n (o) N C pC (M )n (1 − pC (M ))N C −n , if nC (o) > nC (E )
C
n
p − value = 

nC ( o ) N C
pC (M )n (1 − pC (M ))N C −n , if nC (o) < nC (E )
 ∑ 0
n


(5)

This approach takes into consideration the differences in cancer’s mutational rate and rank the pfsSNVs
enriched within cancers despite the sparseness of somatic mutation among patients.
After the log transformation, p-values are visualized in Manhattan plot where horizontal axis represent chromosome from 1 to 23. The cutoff line was calculated as 2E-6 using Bonferroni approach. Lastly, we compared
our prioritized pfsSNVs with a well-known cancer gene list: significantly mutated gene (SMG)32 and cancer gene
census (CGC)33 to further annotate the key pfsSNVs list.

Survival analysis. Identified key pfsSNVs were further investigated to see if any of them significantly affect
patient survival. Patient clinical information was retrieved for TCGA samples from their FTP site (https://
tcga-data.nci.nih.gov/tcgafiles/ftp_auth/distro_ftpusers/anonymous/tumor/). For each key pfsSNV in a specific
cancer type that we identified through the prioritization process, based on the presence of the given pfsSNV,
patients were divided into two groups with clinical factors that may affect patient survival. A log-rank test was
applied to test the death time distributions between two groups. Then the Cox model was used to adjust factors
like age at initial diagnosis, pathological stage and gender. SAS 9.3 was used to perform this analysis.

Results and Discussion

Impact of SNVs on protein functional sites. In this study, we expanded the scope of our previous study8

for better evaluation of mutational profile among various protein PTMs, active and binding sites. Tables 1 and 2
summarizes our data collection for both the current study and our previous study8. Table 1 shows total number
of germline mutation, somatic mutation, and protein functional sites collected in both previous and current
Scientific Reports | 7:42169 | DOI: 10.1038/srep42169
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Figure 2. Synonymous and non-synonymous SNV occurrence ratio among different types of protein
functional site. The values on each axis show, for each PTM type, the percentage of its site occupied by SNVs.
X-axis shows the somatic mutation percentage and Y-axis shows germline mutation percentage. Dot and
triangle markings represent non-synonymous and synonymous mutations respectively. Each protein functional
site type was shown in different color as per the legend. Linear lines in the figure show global ratio for each
mutation type.

datasets. In Table 2, somatic and germline pfsSNV from Table 1 are split into major protein functional site types
and summarized. The number of somatic mutations increased from 994,339 to 1,840,711 (1,272,878 non-synonymous, 476,087 synonymous and 91,746 stop codon). The number of germline mutations increased from 710,946
to 1,501,666 (937,634 non-synonymous, 541,029 synonymous and 23,003 stop codons). The number of protein
functional sites increased from 259,216 to 268,478. After mapping both somatic and germline variations to protein functional site dataset, the number of pfsSNVs increases from 38,549 to 51,138 (31,999 somatic and 19,139
germline). We divided our pfsSNVs into four groups: non-synonymous germline mutation (non-SG), non-synonymous somatic mutation (non-SS), synonymous germline mutation (SG) and synonymous somatic mutation
(SS) because each one of these mutation type has its own biological meaning, and therefore should be analyzed
separately. Additionally, we enlarged the testable SNV dataset by incorporating predicted gain of N-linked glycosylation and phosphorylation site. It is common that SNV caused gain of PTM sites to be ignored in many
HTS based proteome-wide analysis until recently34–36. We found a total number of 344,239 SNVs that cause gain
of phosphorylation sites across 18,259 proteins and 17,921 SNVs that cause gain of N-linked glycosylation sites
across 8,354 proteins.
In Fig. 2, for each protein functional site type, we calculated the percentage of its site impacted by somatic and
germline SNVs (See Supplementary Table 1). In the scatter plot, X-axis and Y-axis indicate somatic and germline
mutation percentages respectively while the dot and triangle represents non-synonymous and synonymous variation percentages respectively. Linear reference lines in the matrix show the global expected percentages. We
can see from Fig. 2, for germline mutations, synonymous (lower reference line on Y axis) and non-synonymous
(upper reference line on Y axis) SNVs cluster near the average reference lines. For somatic variations, synonymous and non-synonymous mutations also cluster near the averages (left reference line on X axis for synonymous; right reference line on X axis for non-synonymous). We can see that pfsSNV occurrence is around the
global average percentages except for crotonylation sites, for which there are much more germline and somatic
SNVs than the average. Outliers on the plot could be caused due to small sample size, for instance, crotonylation
sites has higher synonymous and non-synonymous germline mutation occurrence than reference line but this is
calculated based on just 79 data points.
Instead of just focusing on the exact protein functional sites (such as PTM and active/binding sites) we also
evaluated the preponderance of SNVs upstream and downstream of the functional site. Figure 3, plots all the SNV
occurrence of residues with +/−20 amino acids around the functional site (see Supplementary Table 3a,b,c and d
for plots of all 25 types). In most of the PTM sites, non-synonymous germline mutation (non-SG) shows either
relatively low occurrence or similar rates when compared to neighboring regions. This result is consistent with the
high evolutionary conservation of functional sites15,37. On the other hand, synonymous germline mutation shows
mixed occurrence across different PTMs types with lower than expected occurrences for in some of the sites. It is
interesting to note that several studies have shown that synonymous mutation can affect protein function16,38,39.
Out of 8,357 experimental confirmed acetylation sites in the human proteome, 691 lose acetylation site due
to somatic mutation and 432 lose acetylation site due to germline mutations. In 22,524 ubiquitination sites in the
human proteome, 1,562 ubiquitination sites are lost due to somatic mutations and 1052 ubiquitination sites are
lost due to germline mutations. In comparison with our previous paper, the number of loss of acetylation sites
and ubiquitination sites increased by 48 and 559 respectively. Dysregulation of both acetylation and ubiquitination processes may cause cancer initiation and it has been observed by others that there are frequent mutations
in acetylation and ubiquitination sites which potentially can drive cancer40–42. For acetylation, different modified
sites have distinct regulatory effects, even in the same protein (e.g. malate dehydrogenase 2)41. In another study,
researchers found that both acetylation and deacetylation of p53 on different amino acids could either promote or
block tumorigenesis43. Its complexity leads to the disunity of acetylation function in cancers. Our analysis shows
low non-synonymous somatic (non-SS) mutation occurrence on acetylation sites suggesting that in cancer these
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Figure 3. Occurrence ratio of SNV on the protein functional site neighboring region. Occurrence ratio
of synonymous somatic (SS), synonymous germline (SG), non-synonymous somatic (non-SS) and nonsynonymous germline (non-SG) mutations +/−20 amino acid from protein functional sites. Y-axis shows fold
of change of SNV occurrence on corresponding amino acid position. Different SNV types are represented as
different colors. Value 0 on X-axis indicates the PTM site. T and P represent one sample t-test of the PTM site
comparing with its neighboring. P represents the p-value of corresponding one sample t-test.

sites are still less prone to mutations. In terms of ubiquitination, it can be seen that ubiquitination sites are less
tolerant to SNVs (relatively conserved) compared with its neighboring region.
In our current dataset, we identified 7,373 somatic mutations and 5,282 germline mutations that cause loss
of phosphorylation sites. Previous studies found high enrichment of mutations causing gain or loss of phosphorylation sites and they may be considered as key features in cancer occurrence34. High activity of kinases is
essential to maintain the tumor malignant phenotype (oncogene addiction)44. It is consistent with our result that
non-synonymous mutations (non-SS) show low occurrence at phosphorylation sites. It is also possible that the
low occurrence on phosphorylation site may be caused by the relatively small number of cancer related genes45.
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We identified 2,084 somatic mutations and 1,040 germline mutations that can cause loss of enzyme active
site. In Fig. 3, the non-synonymous somatic mutation occurrence at active site is relatively higher than that at its
surrounding regions. However, when the enzyme active site is considered, its role in cancer is also dependent on
the feature of the protein (oncogene or tumor suppressor gene). For example, in breast cancer, overexpression
of BCRP (breast cancer resistance protein) with its intact active site could cause drug resistance, while mutation
in the active site of α-fetoprotein (AFP) could reduce breast cancer risk46. These mutations can impact enzymes
to metabolize different substrates47, leading to pathological processes. In Fig. 3, the non-synonymous somatic
mutation occurrence at active site is relatively higher than at its surrounding regions. Synonymous somatic
mutation, on the other hand, has a low occurrence rate at active sites. This bias may be caused by the highly
structure-dependent catalytic activity (stable structure is crucial for function)48. At ligand binding sites, 16,630
somatic mutations and 25,074 germline mutations were identified. For binding sites, studies have found their
relationship with disease occurrence in terms of mutations49,50. Binding site analysis shows little SNV occurrence
difference compared to its neighboring regions for SG, SS and non-SS, but overall low mutation occurrence in the
entire functional region for non-SG. However, we would like to mention that binding sites can contain multiple
sites which are not sequentially placed in the sequence. Our analysis focuses on short regions (see materials and
methods), and counting each residue as one binding sites and the immediate region around it thus providing a
practical and comparable evaluation of binding sites and other protein functional sites.
For methylation sites, we identified 208 somatic mutations and 74 germline mutations. It is interesting to note
that the overall occurrence of SG, SS and non-SS is as high as two fold compared to the background occurrence.
In particular, the non-SS mutation occurrence at the methylation sites is relatively higher than other mutation
type and also their surrounding regions. Methylation regulates transcription factor binding affinity, and therefore,
controls the expression level of the downstream target genes51. In consideration of cancer development, previous
study suggests lysine-to-methionine substitution at methylation sites could cause loss of methylation and function in a variety of pathologies. And in our results, the relatively high non-SS mutation occurrence of methylation
may suggest its primary role in either promoting oncogenes or suppressing tumor suppressor genes.
3,217 somatic mutations and 2,630 germline mutations were identified on N-linked glycosylation sites.
Figure 3 also shows that the SNV occurrence at the N-linked glycosylation site and its surrounding amino acids
(−1, +1 and +2) are much higher than others. Non-synonymous somatic mutation shows a deep dip at the
N-linked glycosylation (0.67). In our previous study52, we found slightly lower frequency of all kinds of missense
mutations in N (position 0) than the non-glycosylated motifs. This is also consistent with the higher conservation
of glycoslylated asparagines as compared with the non-glycosylated ones53. Such a low mutation occurrence in
the cancer genome implies its contribution and its role in cancer. In addition, somatic synonymous mutations
(0.89) also show a similar trend at N-linked glycosylation sites. This also suggests that it is important to maintain
N-linked glycosylation site undisrupted. Although, it is quite possible the overall functional impact is maintained
through the heterogeneity of the glycans at the sites in normal vs. cancer tissues54.
The NX(S/T) amino acid sequon (asparagine for N, any amino acid except proline for X, and either serine or
threonine for S/T) is considered as a requirement for N-glycosylation52. This could explain the low occurrence of
the two types of synonymous mutations (germline and somatic) at the amino acid of position +1 (X) but higher
rates for non-synonymous mutation, and high rate (SS: 1.64, SG: 1.75) at position +2 (alternation of serine and
threonine, S/T). Additionally, we found that the amino acid at ‘−1’ position also has lower synonymous germline
mutation occurrence, which suggests possible effects of “silent” mutations at this site.
In terms of O-linked glycosylation, 126 somatic mutations and 115 germline mutations were identified
impacting the PTM site. O-linked glycosylation is known to be important in bearing tumor associated antigens
and also involved in several physiological and pathological processes55–57. One interesting finding is that O-linked
glycosylation sites is the only functional site type showing overall low occurrences across the entire functional site
region in terms of all mutation types (non-SG: 0.60, SG: 0.64, SS: 0.57, non-SS: 0.59).

Pan-cancer view of somatic mutation occurrence on protein functional sites.

For pan-cancer
analysis, cancer Disease Ontology (DO) slim23 was used to unify the cancer types. The observed and expected
somatic mutation occurrence on each functional type was then calculated. Figure 4 shows the pan-cancer
heatmap of somatic mutation occurrences across functional sites (Fig. 4A: non-synonymous, Fig. 4B: synonymous). The mutation occurrence is indicated by ratio of change compared to the cancer type specific global ratio.
Color in the figure indicates either the over-representation (red) or under-representation (blue) of pfsSNVs while
white indicates no SNV occurrence difference between functional sites and neighboring sites. The grey color
indicates the absence of pfsSNVs for the corresponding cancer type. Our assumption is that, since functional sites
are generally conserved, the high/low ratio of somatic pfsSNVs occurrence on these sites implies the loss/gain of
function for them and their possible roles in tumorigenesis.
The pan-cancer view of observed/expected SNVs shown in Fig. 4A displays unique patterns of nsSNV occurrence on functional sites (compared to neighboring site) in different cancer types. The variation occurrence at
ubiquitination and acetylation sites is lower (blue color) at these PTM sites across almost all cancer types. On
the other hand, the methylation site shows higher nsSNV occurrence (red color) in PTM site for majority of
the cancer types. Active sites, binding sites, phosphorylation sites, and N-linked glycosylation sites show insignificant fold-change between PTM sites and neighboring sites. Similarly, for synonymous mutations (Fig. 4B),
ubiquitination and acetylation site show an overall low somatic synonymous mutation occurrence at PTM sites
across almost all the cancer types. However, unlike in non-synonymous mutation, methylation sites show mixed
mutation occurrence across cancer types. Phosphorylation sites and N-linked glycosylation shows an increased
synonymous mutation occurrence in multiple cancer types.
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Figure 4. Pan-caner hierarchical clustering of non-synonymous (A) and synonymous (B) somatic mutation
occurrence on protein functional site region. Figure shows cancer SNV occurrence at PTM site vs somatic SNV
occurrence at a neighboring region for different cancer types. Color indicates fold of change of somatic SNV
occurrence. Red color indicates overrepresentation while blue indicates under-representation. Grey color means
that there is no detected somatic SNV on corresponding PTM type for corresponding cancer.
Identification of key pfsSNVs across multiple cancer types. Out of the 31,999 germline pfsSNVs and 19.139
somatic pfsSNVs, we found that 142 pfsSNVs exist across more than five cancer types, which we considered as
key pfsSNVs (see Supplementary Table 6 for pfsSNVs in more than 3 cancer types). Table 3 displays the top 20
pfsSNVs with respect to number of associated cancer types. In addition, Fig. 5 shows their SNV-functional site
relationship in the Circos plot58. From both Table 3 and Fig. 5 we can see that TP53, one of the most well-known
oncogenes, with 79 out of 142 key pfsSNVs on that protein. We also want to emphasize pfsSNVs that exist on
genes other than TP53. Since TP53 is a well-known oncogene, we emphasize top 20 pfsSNVs associated with multiple cancer types with TP53 excluded in Table 4: NRAS, CTNNB1, NRAS, GNAS, KRAS, HRAS and PTEN. It is
clear that some genes harbor more key pfsSNVs than others as shown in Fig. 5. 14 out of 142 key pfsSNVs, including two of the top 20 pfsSNVs are found within CTNNB1 which is an important component of the canonical
Wnt signaling pathway. It is interesting to note that all these key pfsSNVs are affecting protein phosphorylation
sites between position 29 to 45. This finding confirms previous studies’59 claims that SNVs and overexpression
of CTNNB1 are associated with many cancers: a large number of SNVs cluster on the N-terminal segment of
CTNNB1, the β-TrCP binding motif.
Other than TP53 and CTNNB1, many key members of Ras subfamily, such as NRAS, GNAS, KRAS and
HRAS harbor SNVs across multiple cancer types. Figure 5 shows that virtually all the pfsSNVs on Ras subfamily
are located on binding site. However, multiple alignment of NRAS, GNAS, KRAS and HRAS shows that most
of the key pfsSNVs within these four genes occurs at the same position (RASN_HUMAN Q61), a well-known
position responsible GAP-mediated GTP hydrolysis. SNVs on this residue disturb Ras signaling control and
eventually trigger tumorigenesis by activate genes involved in cell growth, differentiation and survival60.
Identification of key pfsSNVs that are enriched in patients with specific cancer types. To ensure we do not miss
any pfsSNVs that occur repetitively among patients within a specific cancer type, we performed Binomial test
Scientific Reports | 7:42169 | DOI: 10.1038/srep42169
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Gene
Name

UnProtKB
AC

Variation

Functional Site

Cancer
Type Count

TP53

P04637

R273C

Binding Site

31

TP53

P04637

R248Q

Binding Site

28
28

TP53

P04637

R248W

Binding Site

TP53

P04637

R273H

Binding Site

27

TP53

P04637

H179Y

Binding Site

26

NRAS

P01111

Q61K

Binding Site

24

TP53

P04637

C176F

Binding Site

23

TP53

P04637

C275Y

Binding Site

22

NRAS

P01111

Q61R

Binding Site

21

CTNNB1

P35222

T41A

Phosphorylation

21

TP53

P04637

C176Y

Binding Site

20

TP53

P04637

H179R

Binding Site

20

TP53

P04637

K132N

Ubiquitylation

19

TP53

P04637

C238F

Binding Site

19

TP53

P04637

C242F

Binding Site

19

TP53

P04637

R248L

Binding Site

19

TP53

P04637

S241F

Binding Site

18

TP53

P04637

C242Y

Binding Site

18

CTNNB1

P35222

S33C

Phosphorylation

18

TP53

P04637

C238Y

Binding Site

17

Table 3. Top 20 pfsSNVs1 based on the number of associated cancer type count. 1pfsSNV: Protein functional
site affecting SNV.

Figure 5. Circos plot of gene level summarization of 142 key pfsSNVs across five and more cancer types.
Bands are colored by genes, and connect between gene and various types of protein functional sites. Note that,
in 142 key pfsSNVs, all key pfsSNVs on CTNNB1 occur on phosphorylation site and all key pfsSNVs on RAS
subfamily occur on binding site.

using a dataset combining known and predicted gaining/losing pfsSNV sites. This dataset includes 19,337 loss of
functional site causing pfsSNVs, 10,991 gain of N-glycosylation sites, and 208,507 gain of phosphorylation sites.
Log p-values for each pfsSNVs were used for visualization in Fig. 6 (See Supplementary Table 5 for all pfsSNVs
with p-value). Based on our threshold (p-value = 2E-6 using the Bonferroni adjustment), a total number of 77
pfsSNVs (57 gain of phosphorylation site pfsSNVs, 3 gain of glycosylation site pfsSNVs, 12 loss of binding site
pfsSNVs, 3 loss of phosphorylation site and 2 loss of active sites) were identified to be significant in specific cancer
types. Table 5 shows the top 20 pfsSNVs with significant p-value associated with specific cancer types. [L] and
[G] indicate loss of functional site and gain of functional site, respectively. Supplementary Table 5 shows p-values
Scientific Reports | 7:42169 | DOI: 10.1038/srep42169
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Gene
Name

UnprotKB
ID

Variation

NRAS

P01111

Q61K

Binding Site

24

CTNNB1

P35222

T41A

Phosphorylation

21
21

Functional Site

Cancer
Type Count

NRAS

P01111

Q61R

Binding Site

CTNNB1

P35222

S33C

Phosphorylation

18

GNAS

P63092

R201C

Binding Site

16

GNAS

Q5JWF2

R844C

Binding Site

16

KRAS

P01116

Q61H

Binding Site

16

HRAS

P01112

Q61L

Binding Site

15

NRAS

P01111

Q61L

Binding Site

15

PTEN

P60484

R130Q

Active Site

15

CTNNB1

P35222

S33F

Phosphorylation

14

CTNNB1

P35222

S37C

Phosphorylation

14

CTNNB1

P35222

S37F

Phosphorylation

14

CTNNB1

P35222

S45F

Phosphorylation

14

GNAS

P63092

R201H

Binding Site

14

GNAS

Q5JWF2

R844H

Binding Site

14

CTNNB1

P35222

T41I

Phosphorylation

13

CTNNB1

P35222

S45P

Phosphorylation

13

KRAS

P01116

Q61K

Binding Site

13

KRAS

P01116

Q61L

Binding Site

13

Table 4. Top 20 pfsSNVs based on the number of associated cancer type count (TP53 excluded).

Figure 6. Manhattan plot of pfsSNVs enriched in patients with specific cancer types. X-axis indicates
chromosome from 1 to 23 and X, Y in different colors. Each dot in the figure represents a pfsSNV with –log10
(p-value) calculated from a binomial test. Cutoff was set as -log10 (5e-8). A total number of 77 pfsSNVs are
statistically significant in specific cancer type. [L] and [G] indicate loss of PTM/active/binding site and gain
of PTM/active/binding site respectively. As marked in the figure, [L]NRAS-61-Binding Site and [G]PIK3CA545/542-Phosphorylation significantly associate with multiple cancer type.

for all 24,668 pfsSNVs associated with specific cancer type. For example, the gain of phosphorylation site pfsSNV
PIK3CA-545-E-K is significantly associated with as many as six cancer types (63 patients in breast cancer, 28
patients in head and neck cancer, 33 patients in cervical cancer, 19 patients in colon cancer, 14 patients in uterine
cancer, 11 patients in stomach cancer).
Pan-cancer analysis mentioned above identified a total number of 210 key pfsSNVs, among which 142 exist
across more than five cancer types and 77 pfsSNVs are significantly enriched in patients with specific cancer
type. All these 210 key pfsSNVs belong to 60 genes. For the purpose of comparison with key cancer genes found
in other studies, we retrieved the significantly mutated gene (SMG) set found by MutSig suite32 and cancer gene
census (CGC) from COSMIC33. By mapping SMG (260 genes), CGC (573 genes) and key pfsSNVs (60 genes), we
found our key pfsSNVs map to 18 and 20 genes from SMG and CGC respectively. Moreover, we found 17 of them
exist in all three datasets. Table 6 shows the list of these 17 genes with 132 pfsSNVs within them. These 17 genes
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PfsSNVs
[G]2PIK3CA-E545K-Phosphorylation
[L]NRAS-Q61R-Binding Site

Cancer Type

PfsSNVs
Associated
Sample

Total
Sample

P-Value

DOID:1612/breast cancer

63

973

9.62E-85

DOID:4159/skin cancer

44

370

9.94E-51

[G]PIK3CA-E542K-Phosphorylation

DOID:1612/breast cancer

41

973

4.43E-48

[G]CDC27-A274D-Phosphorylation

DOID:1793/pancreatic cancer

44

210

1.59E-41

[G]PIK3CA-E545K-Phosphorylation

DOID:4362/cervical cancer

33

198

5.25E-36

[G]KRTAP4-L161V-Phosphorylation

DOID:1793/pancreatic cancer

39

210

7.70E-35

DOID:4159/skin cancer

33

370

2.91E-34

[G]ANKRD36-T998S-Phosphorylation

DOID:1793/pancreatic cancer

37

210

2.94E-32

[G]EVPL-R336S-Phosphorylation

DOID:1793/pancreatic cancer

36

210

5.47E-31

DOID:11934/head and neck cancer

28

508

1.92E-29

DOID:363/uterine cancer

28

305

4.59E-29

DOID:1793/pancreatic cancer

34

210

1.72E-28

[L]TP53-R273C-Binding Site

DOID:1319/brain cancer

31

287

8.97E-27

[L]NRAS-Q61R-Binding Site

DOID:1781/thyroid cancer

27

390

3.68E-26

[G]UPF3A-V70L-Phosphorylation

DOID:1793/pancreatic cancer

31

210

7.35E-25

[G]KRT8-R23C-Phosphorylation

DOID:1793/pancreatic cancer

29

210

1.61E-22

[L]MEF2A-Y105C-Phosphorylation

DOID:1793/pancreatic cancer

27

210

3.02E-20

[G]ZNF814-A337V-Phosphorylation

DOID:1793/pancreatic cancer

27

210

3.02E-20

[G]SALL1-S159G-Phosphorylation

DOID:1793/pancreatic cancer

26

210

3.88E-19

[L]NRAS-Q61K-Binding Site

[G]PIK3CA-E545K-Phosphorylation
[L]PTEN-R130G-Active Site
[G]NCOR1-Y20S-Phosphorylation

Table 5. Top 20 pfsSNVs enriched in patients with specific cancer type (full list in Supplementary Table 5).
[L]1: Loss of protein functional site. [G]2: Gain of protein functional site.

and their key pfsSNVs which are 1) present in the list of 260 SMG set, 2) present in the list of 573 CGC gene set,
3) have key pfsSNVs which either exist across multiple cancer types or are significantly associated with specific
cancer type.
Existing knowledge on 132 key pfsSNVs. Many of these 132 pfsSNVs and their genes have been described in the
previous studies. One study showed BRAF is commonly activated by somatic point mutation in human cancer,
and may suggest therapeutic potentials particularly in malignant melanoma61. The BRAF L597R missense mutation, which falls in the protein’s kinase domain, has been reported in primary ovarian cancer (OV)61 and lung adenocarcinoma (LUAD), and may become a chemotherapy target for a subset of LUAD patients. CTNNB1 mutation
are found in the GSK3-beta phosphorylation sites, such as S37, T41, and such mutations have been implicated in
ovarian tumorigenesis62. It has been also suggested that CTNNB1 has a higher rate of phosphorylation-related
mutations in skin cancer and performs a critical role in hair matrix cell cancer development63. The EGFR T790M
alteration is called the “gatekeeper” mutation, which is frequently described in lung cancers; it mediates resistance to maximally tolerated dosing of HKI-272 as well as EGFR kinase inhibitors (gefitinib and erlotinib) in
about half of cases64–66. One study also indicated that this drug resistance mutation may also be linked with lung
cancer genetic susceptibility67. HRAS shows high incidence of activating mutations at Q61 in drug-induced skin
cancer68–70. As for KRAS mutations at Q61 in lung cancer, Q61R is observed in a great portion of urethane-induced
tumors from wild-type mice, however, Q61L appears in the majority of tumors from KRAS heterozygous mice.
KRAS Q61 mutations may also play an important role in melanoma photocarcinogenesis71. NRAS Q61 is predominant in malignant melanoma, being a potential therapeutic target in this cancer72. Mutated NRAS at Q61
also shares similarities in signaling among various cancer types, and inhibition of both the MAPK and PI3K/
AKT/mTOR pathways reduces cell viability in all cancers harboring this mutation73. IDH1 mutation at R132 is
demonstrated to be tissue-specific, and may play a special role in high-grade gliomas with prognostic value for
survival74,75. IDH1 and IDH2 mutations are common in AML (acute myeloid leukemia), and are associated with
the accumulation of metabolite 2-hydroxyglutarate, which is affected by neomorphic enzyme activity76–78.

Identification of key pfsSNVs that affect patient survival.

Although there are many studies that
attempt to connect mutations to patient survival there are very few attempts to connect loss or gain of protein
function to mortality. Identifying SNVs that directly lead to gain or loss of functional sites can help biologists
focus on specific biochemical processes that might be impacted due to the variation. The amount of clinical data
available from TCGA is limited because of the length of the study and the type of information that has been
collected so far. Nonetheless, it is possible to showcase how one can filter SNVs for further evaluation which can
assist in translating genomics efforts to actionable therapeutics and diagnostics. Below is an example of how such
analysis can be performed.
We started from the pool of above identified 77 key pfsSNVs that are significantly enriched in a specific cancer type after adjusting multiple testing. Then we grouped patients based on ‘having’ or ‘not having’ a pfsSNV.
From Cox regressions adjusting for age at initial pathological diagnosis, gender and clinical stage 27 out of the
77 mutations increase the risk of cancer (Hazard Ratio >1). Most of the candidate pfsSNVs occur in very small

Scientific Reports | 7:42169 | DOI: 10.1038/srep42169

11

www.nature.com/scientificreports/

UniProtAC

Variation

Functional site

Gene
Name

UniProtAC

Variation

Functional site

BCOR

Q6W2J9

N1459S

[G]Phosphorylation

TP53

P04637

N239D

[L]Binding Site

BRAF

P15056

L597R

[L]Binding Site

TP53

P04637

C242S

[L]Binding Site

CTNNB1

P35222

T41A

[L]Phosphorylation

TP53

P04637

R273L

[L]Binding Site

CTNNB1

P35222

S33C

[L]Phosphorylation

TP53

P04637

R280T

[L]Binding Site

CTNNB1

P35222

S33F

[L]Phosphorylation

TP53

P04637

N239S

[L]Binding Site

CTNNB1

P35222

S37C

[L]Phosphorylation

TP53

P04637

C275F

[L]Binding Site

CTNNB1

P35222

S37F

[L]Phosphorylation

TP53

P04637

C176S

[L]Binding Site

CTNNB1

P35222

S45F

[L]Phosphorylation

TP53

P04637

H179L

[L]Binding Site

CTNNB1

P35222

T41I

[L]Phosphorylation

TP53

P04637

R273S

[L]Binding Site

CTNNB1

P35222

S45P

[L]Phosphorylation

TP53

P04637

C238S

[L]Binding Site

CTNNB1

P35222

S33Y

[L]Phosphorylation

TP53

P04637

R273P

[L]Binding Site

Gene Name

CTNNB1

P35222

S37Y

[L]Phosphorylation

TP53

P04637

A276P

[L]Binding Site

CTNNB1

P35222

S33P

[L]Phosphorylation

TP53

P04637

R280G

[L]Binding Site

CTNNB1

P35222

S37A

[L]Phosphorylation

TP53

P04637

C238R

[L]Binding Site

CTNNB1

P35222

S37P

[L]Phosphorylation

TP53

P04637

S241Y

[L]Binding Site

CTNNB1

P35222

S33A

[L]Phosphorylation

TP53

P04637

R280S

[L]Binding Site

CTNNB1

P35222

S45C

[L]Phosphorylation

TP53

P04637

H179Q

[L]Binding Site

CTNNB1

P35222

S45Y

[L]Phosphorylation

TP53

P04637

S241C

[L]Binding Site
[L]Binding Site

EGFR

P00533

T790M

[L]Binding Site

TP53

P04637

C242R

HRAS

P01112

Q61L

[L]Binding Site

TP53

P04637

C277F

[L]Binding Site

HRAS

P01112

Q61K

[L]Binding Site

TP53

P04637

H179D

[L]Binding Site

HRAS

P01112

Q61R

[L]Binding Site

TP53

P04637

H179N

[L]Binding Site

HRAS

P01112

Q61H

[L]Binding Site

TP53

P04637

R273G

[L]Binding Site

IDH1

O75874

R132H

[L]Binding Site

TP53

P04637

C277Y

[L]Binding Site

IDH1

O75874

R132C

[L]Binding Site

TP53

P04637

S241A

[L]Binding Site

IDH1

O75874

R132G

[L]Binding Site

TP53

P04637

C242W

[L]Binding Site

IDH1

O75874

R132L

[L]Binding Site

TP53

P04637

R248G

[L]Binding Site

IDH1

O75874

R132S

[L]Binding Site

TP53

P04637

R248P

[L]Binding Site

IDH2

P48735

R172K

[L]Binding Site

TP53

P04637

R280I

[L]Binding Site

IDH2

P48735

R172S

[L]Binding Site

TP53

P04637

C176R

[L]Binding Site

KRAS

P01116

Q61H

[L]Binding Site

TP53

P04637

C275W

[L]Binding Site
[L]Binding Site

KRAS

P01116

Q61K

[L]Binding Site

TP53

P04637

C176W

KRAS

P01116

Q61L

[L]Binding Site

TP53

P04637

C275R

[L]Binding Site

KRAS

P01116

Q61R

[L]Binding Site

TP53

P04637

A276D

[L]Binding Site

NCOR1

O75376

Y20S

[G]Phosphorylation

TP53

P04637

A276T

[L]Binding Site

NRAS

P01111

Q61R

[L]Binding Site

TP53

P04637

R337C

[L]Methylation

NRAS

P01111

Q61K

[L]Binding Site

TP53

P04637

R213L

[L]Methylation

NRAS

P01111

Q61L

[L]Binding Site

TP53

P04637

R110L

[L]Methylation

NRAS

P01111

Q61H

[L]Binding Site

TP53

P04637

R213Q

[L]Methylation

NRAS

P01111

Q61E

[L]Binding Site

TP53

P04637

R110P

[L]Methylation

PIK3CA

P42336

E545K

[G]Phosphorylation

TP53

P04637

R213P

[L]Methylation

PIK3CA

P42336

E542K

[G]Phosphorylation

TP53

P04637

R337L

[L]Methylation

PIK3CA

P42336

N345K

[G]Phosphorylation

TP53

P04637

R110C

[L]Methylation

PIK3R1

P27986

N564D

[L]Binding Site

TP53

P04637

R209K

[L]Methylation

PTEN

P60484

R130G

[L]Active Site

TP53

P04637

R337H

[L]Methylation

PTEN

P60484

R130Q

[L]Active Site

TP53

P04637

S215R

[L]Phosphorylation

PTEN

P60484

D92E

[L]Active Site

TP53

P04637

T155N

[L]Phosphorylation

PTEN

P60484

Y155C

[L]Phosphorylation

TP53

P04637

T155I

[L]Phosphorylation

PTEN

P60484

Y68H

[L]Phosphorylation

TP53

P04637

S215I

[L]Phosphorylation

RB1

P06400

R661W

[L]Binding Site

TP53

P04637

T211I

[L]Phosphorylation

SF3B1

O75533

K700E

[L]Ubiquitylation

TP53

P04637

T155P

[L]Phosphorylation

SMAD4

Q13485

R361H

[L]Binding Site

TP53

P04637

S215G

[L]Phosphorylation

SMAD4

Q13485

R361C

[L]Binding Site

TP53

P04637

S215N

[L]Phosphorylation

TP53

P04637

R273H

[L]Binding Site

TP53

P04637

T155A

[L]Phosphorylation

TP53

P04637

H179Y

[L]Binding Site

TP53

P04637

T284P

[L]Phosphorylation

TP53

P04637

C176F

[L]Binding Site

TP53

P04637

K132N

[L]Ubiquitylation

Continued
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UniProtAC

Variation

Functional site

Gene
Name

UniProtAC

Variation

Functional site

TP53

P04637

C275Y

[L]Binding Site

TP53

P04637

K132R

[L]Ubiquitylation

TP53

P04637

C176Y

[L]Binding Site

TP53

P04637

K132E

[L]Ubiquitylation

TP53

P04637

H179R

[L]Binding Site

TP53

P04637

K132M

[L]Ubiquitylation

TP53

P04637

C238F

[L]Binding Site

TP53

P04637

K132Q

[L]Ubiquitylation

Gene Name

TP53

P04637

C242F

[L]Binding Site

TP53

P04637

K139N

[L]Ubiquitylation

TP53

P04637

R248L

[L]Binding Site

TP53

P04637

K132T

[L]Ubiquitylation

TP53

P04637

S241F

[L]Binding Site

TP53

P04637

K164E

[L]Acetylation

TP53

P04637

C242Y

[L]Binding Site

TP53

P04637

R273C

[L]Binding Site

TP53

P04637

C238Y

[L]Binding Site

TP53

P04637

R248Q

[L]Binding Site

TP53

P04637

R280K

[L]Binding Site

TP53

P04637

R248W

[L]Binding Site

Table 6. 132 pfsSNVs that satisfy key pfsSNVs identification criteria. Key pfsSNVs identification criteria:
gene present in the list of 260 significantly mutated gene (SMG) set; gene present in the list of 573 cancer gene
consensus (CGC) gene set; pfsSNV either exists across multiple cancer types or significantly associates with
specific cancer type.

Figure 7. Kaplan-Meier plot of pancreatic cancer patient survival based on the existence of MEF2A-105Y-C-Phosphorylation. X-axis indicate days of survival and Y-axis indicates survival probability. Red and blue
lines indicate survival time of pancreatic cancer patients with and without such mutation respectively. Log-rank
test shows that, comparing with patients with MEF2A-105-Y-C-Phosphorylation, patients without this pfsSNV
survive significantly longer with adjusted p-value of 0.0255. The hazard ratio is 2.348.
number of patients, and sometimes no death case has been observed in the small number of patients with the
candidate pftSNVs, in which cases data cannot provide a valid hazard ratio estimate. We identified 3 pfsSNVs
causing significant higher or lower mortality risks (See Fig. 7, Supplementary Figures 1 and 2). One example
found in pancreatic cancer patients with and without the MEF2A-Y105C-Phosphorylation site was found to have
statistically significant different mortality risk (p-value = 0.0012) from a log-rank test. Even after adjusting for
age at initial diagnosis, pathological stage and gender using a Cox model, the mortality risks in the presence of
MEF2A-Y105C is 2.348 times higher than those without MEF2A -Y105C (adjusted p-value =  0.0255). Figure 7
shows that the Kaplan-Meier estimates in the survival probabilities over days since diagnosis of the two groups are
well separated. MEF2A is a transcriptional factor which binds to MEF2 element and activates numerous growth
factors. It plays diverse roles in the control of cell growth, survival and apoptosis79–81. Although many studies have
been performed on MEF2’s role in muscle and neuron, its role in pancreatic cancer remains unclear.
Although we found few pfsSNVs which appear to be associated with survival, we would like to point out
the limitation of the survival analysis as our sample size is quite small among ‘having mutation’ group and ‘no
mutation’ groups. When no death has been observed in the small group of participants with a specific mutation,
the impact of the pftSNV on mortality are not estimable. Because no studies can enroll an infinite sample size or
follow participants indefinitely, this analysis has no intention to overcome this inherent limitation of data, while
just as we stated in the beginning of this section, it serves a showcase of potential impact of pfsSNVs to evoke
more interest for follow-up studies.
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Conclusion

We have comprehensively investigated the interplay between protein functional sites and SNVs. Each type of
protein functional site shows a distinct SNV frequency in synonymous somatic mutations, synonymous germline
mutations, non-synonymous somatic mutations, and non-synonymous germline mutations. Our experiments
show that, at least for the majority of protein functional site types, non-synonymous germline mutations occur
less frequently. We believe that these sites are, as expected, more evolutionarily conserved because of their functionality. Except for acetylation and ubiquitination sites, other protein functional site types show diverse variation
frequencies between synonymous germline SNVs, synonymous somatic SNVs and non-synonymous somatic
SNVs. Investigation of whether the protein functional sites of tumor tissue tends to accumulate or reject SNVs at
functional sites provides insights on the effect of SNVs impacting each type of protein functional sites. For synonymous variations, although previous studies show that such variations can affect protein function by changing
expression level, current understanding of the effects of synonymous mutations is still limited. However, some
protein functional site types show significant synonymous variation frequency changes, for example, O-linked
glycosylation site contains significantly high frequency of both germline (t statistic =  −19.35, p-value =  6.5E-22)
and somatic mutation (t statistic =  −16.54, p-value =  1.80E-19).
Although a number of studies have been conducted to discover significant mutated genes in cancer82–84, our
study takes steps forward by targeting the impact of key SNVs on amino acids which can be further evaluated
through wet-laboratory experimentations. The top pfsSNVs exist among well-known oncogenes, such as DNA
binding sites and zinc binding sites within TP53, and GEF interaction sites within NRAS. This study identified
several highly mutated regions such as position 29–45 in CTNNB1. To make the key pfsSNVs comprehensive, we
conducted a binomial test using both loss and gain of functional site causing pfsSNVs. This approach identified
77 pfsSNVs enriched in patients with specific cancer types which are good candidates for further investigation
in terms of their biological function and effect in tumor growth. The identification of key pfsSNVs has its value
not only in facilitating the investigation of tumorigenesis mechanism, but also in evaluating the risk of developing cancer. Identified pfsSNVs can be further evaluated using resources such as MutationAligner85,86, and other
mutation analysis services87–89.
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